BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded BioCryst Pharmaceuticals from “strong-buy” to “buy,” while the broader analyst consensus remains “Moderate Buy,” with eight Buy and four Hold ratings and an average price target of $20.60.
• BioCryst shares opened at $9.82, near their 50-day average, and remain well below the consensus target. The stock has traded between $6.00 and $11.22 over the past year.
• The company beat quarterly expectations, reporting $0.30 in earnings per share versus $0.15 expected and revenue of $218.25 million versus $183.28 million; revenue increased 33.6% year over year, although the company remains unprofitable.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) was downgraded by Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research report issued on Saturday.

Other equities analysts also recently issued reports about the stock. Wedbush decreased their price objective on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an "outperform" rating on the stock in a report on Thursday, August 6th. HC Wainwright reaffirmed a "buy" rating and set a $32.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, June 30th. Weiss Ratings reiterated a "hold (c)" rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st. Needham & Company LLC decreased their price target on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a "buy" rating on the stock in a research note on Wednesday, May 6th. Finally, Royal Bank Of Canada lowered their price target on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an "outperform" rating on the stock in a report on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $20.60.

BioCryst Pharmaceuticals Trading Down 0.5%

NASDAQ BCRX opened at $9.82 on Friday. The firm's fifty day moving average price is $9.71 and its two-hundred day moving average price is $9.05. BioCryst Pharmaceuticals has a 1 year low of $6.00 and a 1 year high of $11.22. The firm has a market capitalization of $2.51 billion, a P/E ratio of -6.55 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 EPS for the quarter, beating analysts' consensus estimates of $0.15 by $0.15. The company had revenue of $218.25 million during the quarter, compared to the consensus estimate of $183.28 million. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The company's quarterly revenue was up 33.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.15 EPS. On average, research analysts anticipate that BioCryst Pharmaceuticals will post -2.25 EPS for the current fiscal year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of BioCryst Pharmaceuticals in the second quarter valued at about $238,930,000. RA Capital Management L.P. acquired a new stake in BioCryst Pharmaceuticals in the 4th quarter worth about $123,452,000. Jupiter Topco LLC acquired a new stake in BioCryst Pharmaceuticals in the 2nd quarter worth about $95,268,000. Deerfield Management Company L.P. boosted its holdings in BioCryst Pharmaceuticals by 159.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company's stock valued at $92,363,000 after purchasing an additional 7,477,000 shares during the period. Finally, Janus Henderson Group PLC boosted its holdings in BioCryst Pharmaceuticals by 7,807.2% in the 4th quarter. Janus Henderson Group PLC now owns 7,404,386 shares of the biotechnology company's stock valued at $57,791,000 after purchasing an additional 7,310,745 shares during the period. Institutional investors and hedge funds own 85.88% of the company's stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company's first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source